Category Archives: Stell Cell Research


Stem cell researcher takes on the brain’s fight against age-related diseases – USC News

What happens to the stem cells in our brains as we age? Albina Ibrayeva, a PhD student in the USC Stem Cell laboratory of Michael Bonaguidi, addresses this question as she tries to understand how the brain naturally fights against aging and suggests promising therapeutic avenues for treating age-related neurodegeneration, disease and disorders.

I love science. As an undergraduate student back in Kazakhstan, I constantly sought ways to put my knowledge into practice. During my sophomore year, I interned at the National Center for Biotechnology in Astana. This experience enabled me to work with some of the brightest minds dedicated to scientific research in my country and showed me the meaningfulness of a career in biomedical research. Since then, I knew that I wanted to be a scientist.

I won a scholarship and was accepted to graduate school at USC, first to study biomedical engineering as a masters student, then the biology of aging as a PhD student. In 2015, I joined Michael Bonaguidis lab. So here I am, excited and really passionate about contributing to a not-so-distant future where research and medicine advance all humans well-being.

USC is one of the worlds top research universities, especially for someone who is studying neuroscience, stem cells and aging. The synergy among the LAC-USC Medical Center, the Alzheimers Disease Research Center, the Geriatric Studies Center, the Alzheimers Therapeutic Research Institute, the Laboratory of NeuroImaging, the Zilkha Neurogenetic Institute and USCs stem cell research center provides one of the best avenues to do great research and advance clinical and basic science.

Not only I am blessed to work at USC, but also I like the fact that we are surrounded by the best universities, such as Caltech and the University of California campuses in L.A., San Diego, San Francisco and Santa Barbara with whom we collaborate. California is known to be the most progressive place on Earth in science, technology and innovation. That is why I think I am in the right place, where I too can contribute to science and research on aging and its effects.

After graduating from the USC PhD program, I would like to work as a professor and researcher at a U.S. university. It is one of my dreams to be able to share my knowledge and being a professor would allow me to do so, while continuing my research to benefit U.S. health care and the science of aging.

Research, of course, is and will remain a big part of my life. Science is there to help people who are suffering from different diseases and disorders. In particular, stem cell research has a great potential for its therapeutic application across fields. Science can be really challenging. However, at the same time it is really exciting, and I am a firm believer that science is changing and will change the world, if given a chance.

In high school, I was a professional volleyball player. But then I realized that I dont want to pursue a career in sports, but science.

Sometimes it is hard to stay active, especially when all day long you are analyzing your data, conducting experiments and running simulations on your computer. But whenever I have free time, I try to spend it being as active as possible. I try to hike at least once a week. The Santa Monica Mountains are the best place to hike, with their breathtaking views of the Pacific Ocean, native California grasslands, famous Malibu beaches, and even some historical and cultural sites of Native American life. This is what makes me happy outside of science.

More stories about: Aging, First-Generation Students, Research, Stem Cells

Newly arrived scientist contributes brain power to stem cell research at USC.

One of 11 new postdoctoral fellows receives support from USC and Mexicos equivalent of the National Science Foundation.

Stem cell researcher Michael Bonaguidi considers the science and fiction behind a new movie about a man who wants to live forever.

Global study reveals thinning of gray matter in brain regions responsible for inhibition and emotion.

Excerpt from:
Stem cell researcher takes on the brain's fight against age-related diseases - USC News

Stem cell researcher takes on the brain’s fight against age-related … – USC News

What happens to the stem cells in our brains as we age? Albina Ibrayeva, a PhD student in the USC Stem Cell laboratory of Michael Bonaguidi, addresses this question as she tries to understand how the brain naturally fights against aging and suggests promising therapeutic avenues for treating age-related neurodegeneration, disease and disorders.

I love science. As an undergraduate student back in Kazakhstan, I constantly sought ways to put my knowledge into practice. During my sophomore year, I interned at the National Center for Biotechnology in Astana. This experience enabled me to work with some of the brightest minds dedicated to scientific research in my country and showed me the meaningfulness of a career in biomedical research. Since then, I knew that I wanted to be a scientist.

I won a scholarship and was accepted to graduate school at USC, first to study biomedical engineering as a masters student, then the biology of aging as a PhD student. In 2015, I joined Michael Bonaguidis lab. So here I am, excited and really passionate about contributing to a not-so-distant future where research and medicine advance all humans well-being.

USC is one of the worlds top research universities, especially for someone who is studying neuroscience, stem cells and aging. The synergy among the LAC-USC Medical Center, the Alzheimers Disease Research Center, the Geriatric Studies Center, the Alzheimers Therapeutic Research Institute, the Laboratory of NeuroImaging, the Zilkha Neurogenetic Institute and USCs stem cell research center provides one of the best avenues to do great research and advance clinical and basic science.

Not only I am blessed to work at USC, but also I like the fact that we are surrounded by the best universities, such as Caltech and the University of California campuses in L.A., San Diego, San Francisco and Santa Barbara with whom we collaborate. California is known to be the most progressive place on Earth in science, technology and innovation. That is why I think I am in the right place, where I too can contribute to science and research on aging and its effects.

After graduating from the USC PhD program, I would like to work as a professor and researcher at a U.S. university. It is one of my dreams to be able to share my knowledge and being a professor would allow me to do so, while continuing my research to benefit U.S. health care and the science of aging.

Research, of course, is and will remain a big part of my life. Science is there to help people who are suffering from different diseases and disorders. In particular, stem cell research has a great potential for its therapeutic application across fields. Science can be really challenging. However, at the same time it is really exciting, and I am a firm believer that science is changing and will change the world, if given a chance.

In high school, I was a professional volleyball player. But then I realized that I dont want to pursue a career in sports, but science.

Sometimes it is hard to stay active, especially when all day long you are analyzing your data, conducting experiments and running simulations on your computer. But whenever I have free time, I try to spend it being as active as possible. I try to hike at least once a week. The Santa Monica Mountains are the best place to hike, with their breathtaking views of the Pacific Ocean, native California grasslands, famous Malibu beaches, and even some historical and cultural sites of Native American life. This is what makes me happy outside of science.

More stories about: Aging, First-Generation Students, Research, Stem Cells

Newly arrived scientist contributes brain power to stem cell research at USC.

One of 11 new postdoctoral fellows receives support from USC and Mexicos equivalent of the National Science Foundation.

Stem cell researcher Michael Bonaguidi considers the science and fiction behind a new movie about a man who wants to live forever.

Global study reveals thinning of gray matter in brain regions responsible for inhibition and emotion.

Go here to see the original:
Stem cell researcher takes on the brain's fight against age-related ... - USC News

HemaCare Will Attend the International Society of Stem Cell … – Business Wire (press release)

LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Stem Cell Research (ISSCR) June 14-17 in Boston, MA. The conference celebrates its 15th year by bringing together over 3,000 attendees from around the world to discuss recent innovation in stem cell research and regenerative medicine. This years conference program emphasizes translation of stem cell research to the clinic, with plenary sessions on ethical implications of stem cell therapy as well as preparation and safety of stem cells for the clinical setting.

Our customers are on the cutting edge of developing new cell-based therapies using immune stem cells collected and processed in our laboratory, said Pete van der Wal, HemaCares Chief Executive Officer.We are attending ISSCR to meet with customers and to hear about the latest developments and needs in stem cell research so we may better serve the scientists in this exciting and rapidly evolving field.

Visit HemaCare and meet several members of our sales, marketing, and executive team at the Boston Convention and Exhibition Center, Booth #906, or view our product story at http://www.hemacare.com.

About HemaCare

HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through 39 years in the business of blood collection, processing and storage. In addition, we have established a robust donor recruitment and management system which supports an extensive registry of well-characterized repeat donors. HemaCares controlled procedures ensure a readily available inventory of high-quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCares products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes (phenotypic or disease state, for example), or sub-sets of immune cells that can be selected in our laboratory using the latest technology. HemaCares products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies. For more information, please visit http://www.hemacare.com.

Read the original here:
HemaCare Will Attend the International Society of Stem Cell ... - Business Wire (press release)

Scientists set to trial new stem cell therapy to ‘reawaken’ the brain AFTER death – The Sun

A US company has revealed it will start tests in an unidentified country in Latin America later this year

ATTEMPTS to bring people back from the dead could start in a few months, its been reported.

A US company has revealed it will start new stem cell therapy trials in an unidentified country in Latin America later this year.

Getty Images

In the majority of countries, to be officially declared dead requires an complete and irreversible loss of brain function.

But Bioquark says it has developed a series of injections that can reboot the brain and bring people back to life, according to MailOnline.

CEO Ira Pastor revealed the firm will begin testing itsmethod on humans and have no plans to try it out on animals first.

Pastor and orthopaedic surgeon Himanshu Bansal initially hoped to carry out tests in India last year.

Butthe Indian Council of Medical Research pulled the plug on their plans and asked them to to take the trials elsewhere.

In details published on a clinical trials database, scientists plan to examine individuals aged between 15 and 65 who have been declared brain dead from a traumatic brain injury.

They intend to use MRI scans to look for possible signs of brain death reversal before carrying out the trial, which will happen in three stages.

The first step involves harvesting stem cells from the patients own blood before injecting them back into their body.

Then the patient would be given a dose of peptides injected into their spinal cord.

Getty Images

Lastly they would undergo a 15-day course of laser and median nerve stimulation while monitoring the patient with MRI scans.

Consent is likely to be an issue for the researchers as technically all of the patients will be brain dead.

However the study detail states that it can accept written informed consent from the legally acceptable representative of the patient.

The Bioquark trials are part of a broader project called ReAnima, of which Pastor is on the advisory board.

The project explores the potential of cutting edge biomedical technology for human neuro-regeneration and neuro-reanimation.

Speaking to MailOnline last year, Pastor said: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

We pay for your stories! Do you have a story for The Sun Online news team? Email us at tips@the-sun.co.uk or call 0207 782 4368

Read more from the original source:
Scientists set to trial new stem cell therapy to 'reawaken' the brain AFTER death - The Sun

Stem Cell Software Firm Cellara Eyes Mid-June for Commercial … – Xconomy

Xconomy Wisconsin

A 2015 study in the journal PLOS Biology estimated that $28 billion is spent annually in the U.S. on preclinical research that is not reproducible.

One reason for what some researchers have called a crisis in reproducibility is that in certain types of laboratories, some scientists still track their day-to-day research activities in paper notebooksor, worse yet, in their heads. Thats according to Scott Fulton, CEO of Madison, WI-based Cellara. The startup is developing software designed for researchers in stem cell labs that it says can improve reproducibility of experiments and collaboration among groups around the world.

Formed in 2012, Cellara has been working with several organizations in Wisconsin to develop and test its digital tools. The company plans to formally launch its CultureTrax software to the market later this month in Boston at the annual meeting of the International Society for Stem Cell Research.

Stem cells are undifferentiated cells that can be programmed to turn into specific cell types. Fulton says there are about 25,000 stem cell culture labs worldwide. Some of them have computerized systems for tracking cell cultures, he says, but many still use paper.

We interviewed more than 200 stem cell scientists over the last several years, he says. We found that [many] plan, track, and document all of their cell culture work using paper lab notebooks, just like Louis Pasteur did.

The name CultureTrax comes from culture track, which according to company materials refers to a combination of a cell line, container, and protocolthe predefined steps that make up a scientific experiment. Researchers who are growing stem cells can use Cellaras software to document the contents of containersand their individual compartmentsas well as what actions theyve taken within a given protocol. Users can also record observations and upload images to monitor whether cells are morphing or proliferating.

Many researchers who work with stem cells do so while standing or sitting in front of biosafety cabinets. Cellara provides customers with an iPad mount that can be attached to cabinets, so that users can more easily switch between logging information and hands-on work with the cells. The startups Web-based software is designed to run on both mobile devices and computers. Fulton says that stem cell scientists do the bulk of their documentation while sitting at their desks.

Multiple labs at both the Medical College of Wisconsin, which is located in the Milwaukee area, and the University of Wisconsin-Madison are currently using CultureTrax. Another recently signed customer is Kings College London, which has a stem cell and regenerative medicine department.

Alex Vodenlich, vice president of business development at Cellara, says the functions and ease of use of his companys software also makes it a useful tool for training aspiring stem cell technicians.

Cellara has formed a partnership with Madison Collegea nearby school that offers a variety of associate degree programs and certificates, including one in stem cell technologiesto train students using a version of the startups software. The program is supported in part by a $661,000 grant the National Science Foundation awarded the schoolin 2015.

Thats a whole other adjacent markettrying to educate the next generation of stem cell scientists, Vodenlich says.

Cellara has worked with Acumium, another software company based in Madison, to write the code for CultureTrax. Dan Costello, founder and CEO of Acumium, is one of Cellaras larger investors, Fulton says.

The startup has raised about $1.8 million in debt and equity funding to date, Fulton says. He says Cellara has spent about $1.5 million building CultureTrax, and is about 90 percent Next Page

Jeff Buchanan is the editor of Xconomy Wisconsin. Email: jbuchanan@xconomy.com

View post:
Stem Cell Software Firm Cellara Eyes Mid-June for Commercial ... - Xconomy

Stem cell laws and policy in the United States – Wikipedia

Stem cell laws and policy in the United States have had a complicated legal and political history.

Stem cells are cells found in all multi-cellular organisms. They were isolated in mice in 1981, and in humans in 1998.[1] In humans there are many types of stem cells, each with varying levels of potency. Potency is a measure of a cell's differentiation potential, or the number of other cell types that can be made from that stem cell. Embryonic stem cells are pluripotent stem cells derived from the inner cell mass of the blastocyst. These stem cells can differentiate into all other cells in the human body and are the subject of much scientific research. However, since they must be derived from early human embryos their production and use in research has been a hotly debated topic as the embryo most likely is destroyed in the process.

Stem cell treatments are a type of cell therapy that introduce new cells into adult bodies for possible treatment of cancer, diabetes, neurological disorders and other medical conditions. Stem cells have been used to repair tissue damaged by disease or age.[2]Cloning also might be done with stem cells. Pluripotent stem cells can also be derived from Somatic cell nuclear transfer which is a laboratory technique where a clone embryo is created from a donor nucleus. Somatic cell nuclear transfer is also tightly regulated amongst various countries.

Until recently, the principal source of human embryonic stem cells has been donated embryos from fertility clinics. In January 2007, researchers at Wake Forest University reported that "stem cells drawn from amniotic fluid donated by pregnant women hold much of the same promise as embryonic stem cells."[1]

In 2000, the NIH, under the administration of President Bill Clinton, issued "guidelines that allow federal funding of embryonic stem-cell research."[1]

In 1973, Roe v. Wade legalized abortion in the United States. Five years later, the first successful human in vitro fertilization resulted in the birth of Louise Brown in England. These developments prompted the federal government to create regulations barring the use of federal funds for research that experimented on human embryos.[3] In 1995, the NIH Human Embryo Research Panel advised the administration of President Bill Clinton to permit federal funding for research on embryos left over from in vitro fertility treatments and also recommended federal funding of research on embryos specifically created for experimentation. In response to the panel's recommendations, the Clinton administration, citing moral and ethical concerns, declined to fund research on embryos created solely for research purposes,[4] but did agree to fund research on left-over embryos created by in vitro fertility treatments. At this point, the Congress intervened and passed the Dickey-Wicker Amendment in 1995 (the final bill, which included the Dickey Amendment, was signed into law by Bill Clinton) which prohibited any federal funding for the Department of Health and Human Services be used for research that resulted in the destruction of an embryo regardless of the source of that embryo. In 1998, privately funded research led to the breakthrough discovery of human Embryonic stem cells (hESC).

No federal law ever did ban stem cell research in the United States, but only placed restrictions on funding and use, under Congress's power to spend.[5]

In February 2001, George W. Bush requested a review of the NIH's guidelines, and after a policy discussion within his circle of supporters, implemented a policy in August of that year to limit the number of embryonic stem cell lines that could be used for research.[1] (While he claimed that 78 lines would qualify for federal funding, only 19 lines were actually available.[1])

In April 2004, 206 members of Congress, including many moderate Republicans, signed a letter urging President Bush to expand federal funding of embryonic stem cell research beyond what Bush had already supported.

In May 2005, the House of Representatives voted 238-194 to loosen the limitations on federally funded embryonic stem-cell research by allowing government-funded research on surplus frozen embryos from in vitro fertilization clinics to be used for stem cell research with the permission of donors despite Bush's promise to veto if passed. [5] On July 29, 2005, Senate Majority Leader William H. Frist (R-TN), announced that he too favored loosening restrictions on federal funding of embryonic stem cell research.[6] On July 18, 2006, the Senate passed three different bills concerning stem cell research. The Senate passed the first bill, 63-37, which would have made it legal for the Federal government to spend Federal money on embryonic stem cell research that uses embryos left over from in vitro fertilization procedures.[7] On July 19, 2006 President Bush vetoed this bill. The second bill makes it illegal to create, grow, and abort fetuses for research purposes. The third bill would encourage research that would isolate pluripotent, i.e., embryonic-like, stem cells without the destruction of human embryos.

The National Institutes of Health has hundreds of funding opportunities for researchers interested in hESC.[8] In 2005 the NIH funded $607 million worth of stem cell research, of which $39 million was specifically used for hESC.[9]

During Bush's second term, in July 2006, he used his first Presidential veto on the Stem Cell Research Enhancement Act. The Stem Cell Research Enhancement Act was the name of two similar bills, and both were vetoed by President George W. Bush and were not enacted into law. New Jersey congressman Chris Smith wrote a Stem Cell Therapeutic and Research Act of 2005, which was signed into law by President Bush. It provided $265 million for adult stem cell therapy, umbilical cord blood and bone marrow treatment, and authorized $79 million for the collection of cord blood stem cells.

By executive order on March 9, 2009, President Barack Obama removed certain restrictions on federal funding for research involving new lines of human embryonic stem cells.[10] Prior to President Obama's executive order, federal funding was limited to non-embryonic stem cell research and embryonic stem cell research based upon embryonic stem cell lines in existence prior to August 9, 2001. Federal funding originating from current appropriations to the Department of Health and Human Services (including the National Institutes of Health) under the Omnibus Appropriations Act of 2009, remains prohibited under the Dickey Amendment for (1) the creation of a human embryo for research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero.

In a speech before signing the executive order, President Obama noted the following:

In 2011, a United States District Court "threw out a lawsuit that challenged the use of federal funds for embryonic stem cell research."[12] The decision was a case on remand from the United States Court of Appeals for the District of Columbia Circuit.[12][13]

S1909/A2840 is a bill that was passed by the New Jersey legislature in December 2003, and signed into law by Governor James McGreevey on January 4, 2004, that permits human cloning for the purpose of developing and harvesting human stem cells. Specifically, it legalizes the process of cloning a human embryo, and implanting the clone into a womb, provided that the clone is then aborted and used for medical research. Missouri Constitutional Amendment 2 (2006) (Missouri Amendment Two) was a 2006 law that legalized certain forms of embryonic stem cell research in the state.

California voters in November 2004 approved Proposition 71, creating a US$3 billion state taxpayer-funded institute for stem cell research, the California Institute for Regenerative Medicine. It hopes to provide $300 million a year. However, as of June 6, 2006, there were delays in the implementation of the California program and it is believed that the delays will continue for the significant future. [6] On July 21, 2006, Governor Arnold Schwarzenegger (R-Calif.) authorized $150 million in loans to the Institute in an attempt to jump start the process of funding research.[14]

Several states, in what was initially believed to be a national migration of biotech researchers to California,[15] have shown interest in providing their own funding support of embryonic and adult stem cell research. These states include Connecticut [7], Florida, Illinois, Massachusetts [8], Missouri, New Hampshire, New York, Pennsylvania, Texas [9] [10], Washington, and Wisconsin.

Other states have, or have shown interest in, additional restrictions or even complete bans on embryonic stem cell research. These states include Arkansas, Iowa, Kansas, Louisiana, Nebraska, North Dakota, South Dakota, and Virginia. (States play catch-up on stem cells, USA Today, December 2004) Arkansas, Indiana, Louisiana, Michigan, North Dakota and South Dakota have passed laws to "prohibit the creation or destruction of human embryos for medical research."[5]

Policy stances on stem cell research of various political leaders in the United States have not always been predictable.

As a rule, most Democratic Party leaders and high-profile supporters and even rank and file members have pushed for laws and policies almost exclusively favoring embryonic stem cell research.[17] President Bill Clinton supported the NIH's guidelines in 2000.[1] Both the major candidates in 2008 had supported the 2005 and 2007 bills, in particular Hillary Rodham Clinton, Bill Clinton's First Lady, then U. S. Senator for New York,[18] and Barack Obama, then U.S. Senator for Illinois, who promised to sign the EFCA into law, and was a cosponsor of such bills.[19] Massachusetts governor Deval Patrick is also a proponent of embryonic stem cell research. There have been some Democrats who have asked for boundaries be placed on human embryo use. For example, Carolyn McCarthy has publicly stated she only supports using human embryos "that would be discarded".[20][21]

The Republicans largely oppose embryonic stem cell research in favor of adult stem cell research which has already produced cures and treatments for cancer and paralysis for example, but there are some high-profile exceptions who offer qualified support for some embryonic stem cell research.[5] Prominent Republican leaders against embryonic stem cell research include Sarah Palin, Jim Talent, Rick Santorum, and Sam Brownback.[5] In July 2001:

Sen. Bill Frist (R-TN) and Sen. Orrin Hatch (R-UT), a vocal abortion opponent, call[ed] for limited federal funding for embryonic stem-cell research.... House Speaker Dennis Hastert (R-IL) and other Republican House leaders [came] out in opposition to federal funding for embryonic stem cell research.

2008 "GOP" Presidential Candidate John McCain is a member of The Republican Main Street Partnership, and supports embryonic stem cell research,[5] despite his earlier opposition.[22] In July 2008 he said, "At the moment I support stem cell research [because of] the potential it has for curing some of the most terrible diseases that afflict mankind."[23] In 2007, in what he described as "a very agonizing and tough decision," he voted to allow research using human embryos left over from fertility treatments.[24] Former First Lady Nancy Reagan and Senator Orrin Hatch also support stem cell research, after first opposing the issue.[5] Former Senator Frist also supports stem cell research, despite having initially supported past restrictions on embryonic stem cell research. 2008 V.P. candidate Palin opposed embryonic stem cell research, which she said causes the destruction of life, thus this research is inconsistent with her pro-life position and she does not support it.[25] She said, in an interview with Charlie Gibson, that she supports adult stem cell research approaches.[26]

A few moderates or Libertarians support such research with limits. Lincoln Chafee supported federal funding for embryonic stem cell research. Ron Paul, a Republican congressman, physician, and Libertarian and Independent candidate for President, has sponsored much legislation, and has had quite complex positions.

In 2005, the United States National Academies released its Guidelines for Human Embryonic Stem Cell Research. These Guidelines were prepared to enhance the integrity of human embryonic stem cell research in the public's perception and in actuality by encouraging responsible practices in the conduct of that research. The National Academies has subsequently named the Human Embryonic Stem Cell Research Advisory Committee to keep the Guidelines up-to-date.[27]

The guidelines preserve two primary principles. First, that hESC research has the potential to improve our understanding of human health and discover new ways to treat illness. Second, that individuals donating embryos should do so freely, with voluntary and informed consent. The guidelines implement executive order 13505, and apply to hESC research receiving funds from the NIH. The guidelines detail safeguards to protect donating individuals by acquiring informed consent and protecting their identity. In addition, the guidelines contain multiple sections applying to embryos donated in the US and abroad, both before and after the effective date of the guidelines.[28]

The NIH guidelines define which hESC research is eligible to receive NIH funding through a series of regulations which applicants for funding must adhere to. Applicants proposing research, may use stem cell lines that are posted on the NIH registry, or may submit an assurance of compliance with section II of the guidelines. Section II is applicable to stem cells derived from human embryos.[28]

For the purposes of section II of the NIH guidelines, the following requirements must be met. First, the hESCs should have been derived from embryos created using an in vitro fertilization procedure for reproductive purposes, and no longer needed for this purpose. Second, the donors who sought reproductive treatment have given written consent for the embryos to be used for research purposes. Third, all written consent forms and other documentation must be provided.[28]

Documentation must be provided regarding the following: All options available to the healthcare facility regarding the embryos in question were explained to the individual who sought reproductive treatment. No payments of any kind may be offered for the donated embryos. Policies and procedures must be in place at the facility where the embryos were donated to ensure that neither donation nor refusal to donate affects quality of care received by the patient.[28]

There must also be a clear distinction between the donors decision to create embryos for reproductive purposes, and the decision to donate embryos for research. This is ensured through a number of regulations which follow. First, the decision to create embryos for reproductive purposes must have been made without the influence of researchers proposing usage for the embryos to derive hESCs for research purposes. Consent for the donation of embryos should have been given at the time of donation. Finally, donors should have been informed that they have the right to withdraw consent at any time until derivation of stem cells from the embryo, or until the identity of the donor can no longer be linked to the embryo.[28]

When seeking consent from the donor, they must be informed of what will become of their donation. The donor must be informed that the embryonic stem cells would be derived from the embryos from research purposes. The donor must also be informed of the procedures that the embryo would undergo in the derivation process, and that the stem cell lines derived from the embryo may be kept for many years. In addition, the donors must be informed that the donation is not made with direction regarding the intended use of the derived stem cells, and the research is not intended to provide direct medical benefit to the donor. The donor is also to be informed that there may be commercial potential resulting from the research performed, and that the donor is not to benefit from commercial development as a result of the donation. The donor is also to be notified if information that could disclose their identity will be available to the researchers.[28]

Applicants seeking to use stem cell lines established before the effective date of the guidelines may use lines published on the NIH registry, or establish eligibility by complying with the requirements listed above. Alternately, researchers may submit materials to a working group of the Advisory Committee to the Director. The working group will review submitted materials and submit recommendations to the Advisory Committee, which will in turn make recommendations to the NIH director. A final decision regarding eligibility for funding is then made by the NIH director.[28]

The materials submitted to the working group must demonstrate that the stem cells were derived from embryos created for reproductive purposes, and are no longer needed. Also, the materials must demonstrate that the stem cells were donated by donors who had granted voluntary written consent.[28]

Research ineligible for NIH funding as dictated within the guidelines include research in which hESCs are introduced into non-human primate blastocysts. Research of the breeding of animals where hESCs may contribute to the germ line are similarly ineligible. NIH funding of the derivation of stem cells from human embryos is prohibited by the annual appropriations ban on the funding of human embryo research. Research using hESCs derived from other sources is also not eligible for funding.[28]

See the original post:
Stem cell laws and policy in the United States - Wikipedia

Trials of embryonic stem cells to launch in China – Nature.com

Jason Lee/Reuters

Former Chinese leader Deng Xiaoping had Parkinsons disease, one of the first targets of embryonic-stem-cell therapies being tested in China.

In the next few months, surgeons in the Chinese city of Zhengzhou will carefully drill through the skulls of people with Parkinsons disease and inject 4 million immature neurons derived from human embryonic stem cells into their brains. Then they will patch the patients up, send them home and wait.

This will mark the start of the first clinical trial in China using human embryonic stem (ES) cells, and the first one worldwide aimed at treating Parkinsons disease using ES cells from fertilized embryos. In a second trial starting around the same time, a different team in Zhengzhou will use ES cells to target vision loss caused by age-related macular degeneration.

The experiments will also represent the first clinical trials of ES cells under regulations that China adopted in 2015, in an attempt to ensure the ethical and safe use of stem cells in the clinic. China previously had no clear regulatory framework, and many companies had used that gap as an excuse to market unproven stem-cell treatments.

It will be a major new direction for China, says Pei Xuetao, a stem-cell scientist at the Beijing Institute of Transfusion Medicine who is on the central-government committee that approved the trials. Other researchers who work on Parkinsons disease, however, worry that the trials might be misguided.

Both studies will take place at the First Affiliated Hospital ofZhengzhouUniversity in Henan province. In the first, surgeons will inject ES-cell-derived neuronal-precursor cells into the brains of individuals with Parkinsons disease. The only previous trial using ES cells to treat Parkinsons began last year in Australia; participants there received stem cells from parthenogenetic embryosunfertilized eggs that are triggered in the lab to start embryonic development.

In the other Zhengzhou trial, surgeons will take retinal cells derived from ES cells and transplant them into the eyes of people with age-related macular degeneration. The team will follow a similar procedure to that of previous ES-cell trials carried out by researchers in the United States and South Korea.

Qi Zhou, a stem-cell specialist at the Chinese Academy of Sciences Institute of Zoology in Beijing, is leading both efforts. For the Parkinsons trial, his team assessed hundreds of candidates and have so far have picked ten who best match the ES cells in the cell bank, to reduce the risk of the patients bodies rejecting the cells.

The 2015 regulations state that hospitals planning to carry out stem-cell clinical work must use government-certified ES-cell lines and pass hospital-review procedures. Zhous team completed four years of work with a monkey model of Parkinsons, and has met the government requirements, he says.

Parkinsons disease is caused by a deficit in dopamine produced by brain cells. Zhous team will coax ES cells to develop into precursors to neurons, and will then inject them into the striatum, a central region of the brain implicated in the disease.

In their unpublished study of 15 monkeys, the researchers did not observe any improvements in movement at first, says Zhou. But at the end of the first year, the team examined the brains of half the monkeys and found that the stem cells had turned into dopamine-releasing cells. He says that they saw 50% improvement in the remaining monkeys over the next several years. We have all the imaging data, behavioural data and molecular data to support efficacy, he says. They are preparing a publication, but Zhou says that they wanted to collect a full five years worth of animal data.

Jeanne Loring, a stem-cell biologist at the Scripps Research Institute in La Jolla, California, who is also planning stem-cell trials for Parkinsons, is concerned that the Australian and Chinese trials use neural precursors and not ES-cell-derived cells that have fully committed to becoming dopamine-producing cells. Precursor cells can turn into other kinds of neurons, and could accumulate dangerous mutations during their many divisions, says Loring. Not knowing what the cells will become is troubling.

But Zhou and the Australian team defend their choices. Russell Kern, chief scientific officer of the International Stem Cell Corporation in Carlsbad, California, which is providing the cells for and managing the Australian trial, says that in preclinical work, 97% of them became dopamine-releasing cells.

Lorenz Studer, a stem-cell biologist at the Memorial Sloan Kettering Cancer Center in New York City who has spent years characterizing such neurons ahead of his own planned clinical trials, says that support is not very strong for the use of precursor cells. I am somewhat surprised and concerned, as I have not seen any peer-reviewed preclinical data on this approach, he says.

Studers and Lorings teams are part of an international consortium that coordinates stem-cell treatments for Parkinsons. In the next two years, five groups in the consortium plan to run trials using cells fully committed to becoming dopamine-producing cells.

Regenerative neurobiologist Malin Parmar, who heads one of the teams at Lund University in Sweden, says that the groups are all rapidly moving towards clinical trials, and this field will be very exciting in the coming years.

Read the rest here:
Trials of embryonic stem cells to launch in China - Nature.com

Promising possibilities of stem cell research explored at UCalgary event – UCalgary News

Calgary aviation engineer Don Adamson endured a dozen surgeries to keep him alive after a car fire burned 50 per cent of his body.

Adamson remembers paramedics thinking he was dead that day 12 years ago. But he fought back, survived and today is one of the biggest advocates for stem cell researchresearch he believes will eventually improve the quality of life of burn survivors.

Skin grafts just patch you up, and stop the bleeding, he says. Using stem cells potentially enable skin regeneration that will help future burn patients both function and look better.

Adamsons confidence in the research being done into potential clinical applications of stem cells foundation cells for every body organ and tissue that also work to maintain and repair the body throughout life comes, in large part, from his association with University of Calgary Faculty of Veterinary Medicine (UCVM) researcher Jeff Biernaskie.

Biernaskie, who is an associate professor in UCVMs Department of Comparative Biology and Experimental Medicine, is the Calgary Firefighters Burn Treatment Society Chair in Skin Regeneration and Wound Healing. He holds a joint appointment in the Cumming School of Medicine Department of Surgery and is a member of the Alberta Childrens Hospital Research Institute.

In 2014, Biernaskies lab identified the existence of a dermal stem cell in adult hair follicles, a discovery that shed new light on how hair follicles regenerate. His team of multidisciplinary collaborators is studying how that discovery can be used to repair wounded human skin.

Its application would be life-changing for millions of burn victims (30 per cent of whom are children), military personnel hurt in action, and the elderly whose paper-thin skin doesnt heal well.

High school students and adults learn about stem cell research

Adamson and Biernaskie were among the speakers at 5th Annual StemCell Talks, a symposium organized by university students. Nearly 180 students from 15 high schools learned about current stem cell research from cell transplants to treat chronic complications of diabetes, and stem cells for healthy organ creation, to career options related to stem cell science.

For Sana Jawad, a Grade 12 student at Sir Winston Churchill high school, the symposium opened her eyes to a potential research career. Already slated for biological sciences at UCalgary, Jawad was inspired by Adamsons burn survival story.

I thought research would be boring. But I realize now there are real people involved that what you do with science can make a big difference in their lives.

An evening adult session also attracted nearly 100 attendees from the Calgary community interested in learning more about stem cell basics, their potential for future clinical use, as well as their many limitations.

Modern day snake oil salesmen putting desperate sick people at risk

Attendees learned about the health threat posed by what are known as "medical tourism clinics" operating in a variety of countries (including Canada) that claim to heal everything from arthritis, Alzheimers and multiple sclerosis, to heart disease and Parkinsons through unproven stem cell treatments.

Part of Adamsons stem cell research advocacy includes taking on modern day snake oil salesmen in clinics that perpetuate myths of stem cell miracles that can save those desperate for cures.

Ubaka Ogbogu, assistant professor at the University of Alberta, who also spoke at the event, was equally blunt: They are hucksters.

Ogbogu cited cases where desperate, sick people mortgaged their homes to spend tens of thousands of dollars on treatments that only made them worse. He said the clinics take evolving research into private care ahead of science, without proof it is safe or works.

He estimates it will be another 30 years of research (including taking testing from the laboratory to human trials), government approvals and new drug development before legitimate stem cell therapies could be available.

Biernaskie is more optimistic (10-20 years) but agrees, saying scientists are moving forward, but cautiously, because the right types of cells need to be made and then successfully integrated within the human body and they need to restore function. Most importantly, we need to be sure they wont harm the patient.

Read more here:
Promising possibilities of stem cell research explored at UCalgary event - UCalgary News

Trials of Embryonic Stem Cells to Launch in China – Scientific American

In the next few months, surgeons in the Chinese city of Zhengzhou will carefully drill through the skulls of people with Parkinsons disease and inject 4 million immature neurons derived from human embryonic stem cells into their brains. Then they will patch the patients up, send them home and wait.

This will mark the start of the first clinical trial in China using human embryonic stem (ES) cells, and the first one worldwide aimed at treating Parkinsons disease using ES cells from fertilized embryos. In a second trial starting around the same time, a different team in Zhengzhou will use ES cells to target vision loss caused by age-related macular degeneration.

The experiments will also represent the first clinical trials of ES cells under regulations that China adopted in 2015, in an attempt to ensure the ethical and safe use of stem cells in the clinic. China previously had no clear regulatory framework, and many companies had used that gap as an excuse to market unproven stem-cell treatments.

It will be a major new direction for China, says Pei Xuetao, a stem-cell scientist at the Beijing Institute of Transfusion Medicine who is on the central-government committee that approved the trials. Other researchers who work on Parkinsons disease, however, worry that the trials might be misguided.

Both studies will take place at the First Affiliated Hospital ofZhengzhouUniversity in Henan province. In the first, surgeons will inject ES-cell-derived neuronal-precursor cells into the brains of individuals with Parkinsons disease. The only previous trial using ES cells to treat Parkinsons began last year in Australia; participants there received stem cells from parthenogenetic embryosunfertilized eggs that are triggered in the lab to start embryonic development.

In the other Zhengzhou trial, surgeons will take retinal cells derived from ES cells and transplant them into the eyes of people with age-related macular degeneration. The team will follow a similar procedure to that of previous ES-cell trials carried out by researchers in the United States and South Korea.

Qi Zhou, a stem-cell specialist at the Chinese Academy of Sciences Institute of Zoology in Beijing, is leading both efforts. For the Parkinsons trial, his team assessed hundreds of candidates and have so far have picked ten who best match the ES cells in the cell bank, to reduce the risk of the patients bodies rejecting the cells.

The 2015 regulations state that hospitals planning to carry out stem-cell clinical work must use government-certified ES-cell lines and pass hospital-review procedures. Zhous team completed four years of work with a monkey model of Parkinsons, and has met the government requirements, he says.

Parkinsons disease is caused by a deficit in dopamine produced by brain cells. Zhous team will coax ES cells to develop into precursors to neurons, and will then inject them into the striatum, a central region of the brain implicated in the disease.

In their unpublished study of 15 monkeys, the researchers did not observe any improvements in movement at first, says Zhou. But at the end of the first year, the team examined the brains of half the monkeys and found that the stem cells had turned into dopamine-releasing cells. He says that they saw 50% improvement in the remaining monkeys over the next several years. We have all the imaging data, behavioural data and molecular data to support efficacy, he says. They are preparing a publication, but Zhou says that they wanted to collect a full five years worth of animal data.

Jeanne Loring, a stem-cell biologist at the Scripps Research Institute in La Jolla, California, who is also planning stem-cell trials for Parkinsons, is concerned that the Australian and Chinese trials use neural precursors and not ES-cell-derived cells that have fully committed to becoming dopamine-producing cells. Precursor cells can turn into other kinds of neurons, and could accumulate dangerous mutations during their many divisions, says Loring. Not knowing what the cells will become is troubling.

But Zhou and the Australian team defend their choices. Russell Kern, chief scientific officer of the International Stem Cell Corporation in Carlsbad, California, which is providing the cells for and managing the Australian trial, says that in preclinical work, 97% of them became dopamine-releasing cells.

Lorenz Studer, a stem-cell biologist at the Memorial Sloan Kettering Cancer Center in New York City who has spent years characterizing such neurons ahead of his own planned clinical trials, says that support is not very strong for the use of precursor cells. I am somewhat surprised and concerned, as I have not seen any peer-reviewed preclinical data on this approach, he says.

Studers and Lorings teams are part of an international consortium that coordinates stem-cell treatments for Parkinsons. In the next two years, five groups in the consortium plan to run trials using cells fully committed to becoming dopamine-producing cells.

Regenerative neurobiologist Malin Parmar, who heads one of the teams at Lund University in Sweden, says that the groups are all rapidly moving towards clinical trials, and this field will be very exciting in the coming years.

This article is reproduced with permission and wasfirst publishedon May 31, 2017.

Follow this link:
Trials of Embryonic Stem Cells to Launch in China - Scientific American

Texas May Be First To Allow Stem Cell Therapies For Desperate … – Vocativ

A bill may soon grant Texans greater access to unapproved but promising stem cell therapies, Stat News reports. Its passage would make Texasthe first state to back the technology, which has not been approved by federal regulators and many experts consider risky.

The bill, HB 810, is intended to give people with chronic diseases or terminal illnesses access to investigational stem cell treatments those that are being evaluated in clinical trials or that has in general not been approved by the FDA. With a doctors approval, patients who have had not had success withconventional treatments would be allowedto seek stem cell therapiesat any clinic that offers it, as long as the treatment is givenby a licensed physician and approved by an institutional review board.

Already, hundreds of largely unregulated clinics around the country are quietly operatingunder regulatory loopholes; few states have taken legal steps to advance or hinder patient access to them.

Texas has welcomed these clinics for years. In 2011, then-governor Rick Perry received an injection of stem cells intended to help heal his spine after spinal fusion surgery. Lets get Texas in on the ground floor and invest in adult stem cell research, the one area of that field that is actually proven to expedite cures, Perry said at the time, according to ABC News.

Stem cell therapy usually involves extracting a patients fat cells,processing and purifying the stem cellsoutside the body, then re-injecting them to the treatment site.Proponents of stem cell therapies claim that no regulators should be able to keep them from their own cells, which could potentially help ameliorate conditions such as Parkinsons, some types of blindness, or paralysis caused by injuries to the spinal cord. Indeed, some experiments have indicated that stem cells can in fact treat these conditions, including one that paused the progression of multiple sclerosis.

But experts warn that unregulated treatments put desperate patients at risk. They may come with unexpected side effects or adverse eventsone patient developed a spinal tumor after an injection of stem cells in Mexico; three women recently went blind in a clinical trial intended to improve their vision. Plus, theyre expensive and arent covered by insurance. Earlier this month, the president of the International Society for Stem Cell Research penned a letter to Texas legislators stating her opposition to HB 810, and two other pieces of pending legislation that would give patients easier access to unregulated treatments. These bills would cost more lives than they save and would be detrimental to the citizens of Texas.

Stem cell therapies are also at a crossroadsat the federal levellast year, the FDA pushed to crack down on these unregulated clinics, though later in 2016 a bill speeding the agencys review of stem cell treatments became law.

On May 12, the bill overwhelmingly passed the Texas House, without a single vote against. On May 24, it passed the state Senate, too. HB 810 will soon be on Governor Greg Abbotts desk to sign into law. Abbott is expected to do so as he has already expressed his support for the bill, Stat notes.

Originally posted here:
Texas May Be First To Allow Stem Cell Therapies For Desperate ... - Vocativ